GlassScriptPhysician profile
Daniel Francis Lam
NPI 1144311127
$2,975.79
in general payments reported to CMS, 2019-2025
22 companies · $646 in 2025
The $646 reported for 2025 was more than what 79% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $143 · 2021: $168 · 2022: $606 · 2023: $682 · 2024: $329 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,657.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $427.69 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $419.20 | 2023-2025 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $261.07 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $233.93 | 2019-2023 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $211.58 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $203.77 | 2021-2024 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $184.40 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $178.60 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $145.11 | 2020-2024 | Lybalvi, Aristada |
| Corium, LLC | $134.80 | 2023-2024 | Azstarys |
| Abbvie INC. | $121.17 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $115.84 | 2019-2023 | Spravato |
| Vertical Pharmaceuticals, LLC | $69.25 | 2019 | |
| Jazz Pharmaceuticals INC. | $63.94 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $49.42 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $27.77 | 2025 | Cobenfy |
| Bausch Health US, LLC | $24.87 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.67 | 2019 | |
| Noven Therapeutics, LLC | $22.65 | 2024 | Secuado, Xelstrym |
| Idorsia Pharmaceuticals US INC | $20.92 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.38 | 2021 | |
| Lundbeck LLC | $17.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.